In July 2015, Neurotherapeutics published an article about Autism spectrum disorder (ASD), presenting a modern view of the endocannabinoid (eCB) system, and alterations of its main components in human patients and animal models relevant to ASD. Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCB-based therapies have already reached preclinical and clinical phases. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are being developed at a surprising speed. Read More
A study by researchers at Harvard Medical School was published in Molecular Cancer Therapeutics in 2011 characterizing the mechanism underlying the antitumoral properties of cannabidiol (CBD). This study showed that CBD induced both apoptosis and autophagy-induced death in breast cancer cells and inhibited the survival of both estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines. These data enhance the desirability of CBD as an anticancer agent, because they suggest that CBD preferentially kills breast cancer cells, while minimizing damage to normal breast tissue.
In 2005, the British Journal of Pharmacology published a study evaluating the ability of cannabidiol (CBD) to impair the migration of tumor cells and thus act as a potential antitumoral compound. The results of the study reinforce the evidence of antitumoral properties of CBD, demonstrating its ability to limit tumor invasion, although the mechanism of its pharmacological effects remains to be clarified. This antimigratory property, together with the known antiproliferative and apoptotic features of CBD, strengthen the evidence for its use as a potential antitumoral agent.
From a research letter published in JAMA, greater than 50% of products evaluated had significantly less cannabinoid content than labeled, with some products containing negligible amounts of THC. Read More
An article in JAMA: Physicians should educate patients about medical marijuana to ensure that it is used appropriately and that patients will benefit from its use. To effectively do this, they need to educate themselves. Read More
From an original investigation published in JAMA, there was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. Read More
“Evidence justifying marijuana use for various medical conditions will require the conduct of adequately powered, double-blind, randomized, placebo/active controlled clinical trials to test its short-and long-term efficacy and safety. The federal government and states should support medical marijuana research.” Read More
In the current June 2015 issue of Lancet, findings consistent with previous evidence suggest that passage of state medical marijuana laws does not increase adolescent use of marijuana. Whether access to a substance for medical purposes should be determined by legislation rather than biomedical research and regulatory review is debatable. However, concerns that increased adolescent marijuana use is an unintended effect of state medical marijuana laws seem unfounded. Read More
Published in the journal Clinical Chemistry, this research looked at blood and plasma levels of cannabinoids in participants vaporizing cannabis, with and without drinking alcohol. They found that the use of alcohol with cannabis significantly increased the amount of THC in the blood, thus explaining reported observations that cannabis plus alcohol causes Read More
This peer reviewed article from the April 2015 issue of Clinical Research explores the current status of cannabis research, including regulatory challenges & solutions, and discusses the future of the field. Although cannabis is primarily viewed by the public as a recreational drug or agent of abuse, its medical application spans recorded history. Read More